The LEAP-001 study evaluated the combination of Keytruda plus Lenvima for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair ...

The medicine - branded Lenvima - stops cancer cells from multiplying, slowing the disease's progression.

Eisai has filed its cancer drug Lenvima (lenvatinib) in Europe for use against advanced or metastatic renal cell carcinoma (RCC), where its review will be fast-tracked. Lenvima is already approved ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

Lenvima (lenvatinib mesylate) was approved and launched for differentiated thyroid cancer in the US, the EU and Japan last year, and earned 1.3bn yen (around $12m) in the first quarter of 2016.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September ...

Please note that Merck markets Lynparza in partnership with AstraZeneca AZN. Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by ...